Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by retiredcopon Nov 12, 2020 12:45am
117 Views
Post# 31882946

RE:Greed & Incompetence

RE:Greed & IncompetenceI am always game for change for the better, but if it gets to the stage where you have to resort  to a proxy battle, you better have a much better person in mind to take over, andf that person has to be ready to go. Questions like is there a payout clause for any of the board . Are there agreements or contracts without having to get into a prolonged legal battle? Do the contesting shareholders pay for the lawyers or is the company expected to cover the cost?  How much is the new person going to cost us, because we would be wanting a very compotent and experienced person in this position  I would not expect us to just replace him with another of the many unemployed executives that are sitting and waiting to get on the gravy train. These guys rotate in and out of the game like a bunch of sqaure dancers.   

My other concern is that inorder to do this there will be no choice but to consolidate the shares (lets start at 10:1 ) inorder to now have room to cover the compensation for the new positions(s) and if we are going further the purging of the new board members. At this point I dont even know what my share average is being I bought most of my shares at $1.30 - $.80 range. All I do know is I am still out alot of $$$ that I intially invested. 

There is only 1 person that is in this for the better of the company and thats Dr Cashman. Lets admit it.. we are ALL here or staying here because we are it to make money for OURSELVES. So bascially we are all GREEDY in the sense of the word. 

This is my personal outlook and I am sure there are many different ones out there that will fill the pages.  
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse